The abstract is read at the publisher; the summary is JClub's.
Once-weekly oral islatravir/lenacapavir is non-inferior to contemporary daily ART for maintaining virological suppression at 48 weeks in phase 3 ISLEND-1 and ISLEND-2 trials.
- Why it matters: Daily regimens can be hard to sustain, and clinicians need evidence that a simpler weekly oral option can preserve viral control without unacceptable safety tradeoffs.
- What they did: Phase 3 ISLEND-1 and ISLEND-2 compared once-weekly oral islatravir plus lenacapavir against contemporary daily ART, assessing virological suppression at 48 weeks, with adherence, satisfaction, and safety monitored.
- The result: The trials’ results, including high adherence and treatment satisfaction in ISLEND-2 and broadly reassuring safety across both studies, support weekly oral ART as clinically credible despite remaining uncertainties.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.